Who
Patrick Fabbio
Director
Company insider
Files Form 4 as: Director, BeyondSpring; Chief Financial Officer, Protara Therapeutics; CFO & President, Rafael Holdings; CFO, Progenics Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Dec 2015
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | BYSI BeyondSpringoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,165 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BYSI BeyondSpringoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,165 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K3,261 at $6.67 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K3,261 at $6.67 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K3,063 at $5.60 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K3,063 at $5.60 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 21 Apr 2025filed 23 Apr 2025 | BYSI BeyondSpringoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,793 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K3,061 at $4.76 | filing |
| 19 Jan 2024filed 23 Jan 2024 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 19 Jan 2024filed 23 Jan 2024 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 30 Jan 2023filed 30 Jan 2023 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 21 Dec 2022filed 23 Dec 2022 | RFL Rafael HoldingsBiotechnology | SEC FORM 4 Code F | $49K27,928 at $1.76 | filing |
| 1 Feb 2022filed 3 Feb 2022 | RFL Rafael HoldingsBiotechnology | SEC FORM 4 Code A | —363,103 at $0.00 | filing |
| 17 Sep 2021filed 20 Sep 2021 | RFL Rafael Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,602 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.